To include your compound in the COVID-19 Resource Center, submit it here.

Batimastat BiodivYsio stent: BII and BBG started BRILLIANT II, a double-blind, 400-patient pivotal European trial of the Batimastat BiodivYsio stent. The study

Biocompatibles International plc (LSE:BII), Farnham, U.K.
British Biotech plc

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE